New Assays, Enhanced Solutions Drive Momentum - Research Report on Quest Diagnostics, Life Technologies, LabCorp, Health Net,

   New Assays, Enhanced Solutions Drive Momentum - Research Report on Quest
     Diagnostics, Life Technologies, LabCorp, Health Net, and CombiMatrix

PR Newswire

NEW YORK, March 13, 2013

NEW YORK, March 13, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Quest
Diagnostics Incorporated (NYSE: DGX), Life Technologies Corporation (NASDAQ:
LIFE), Laboratory Corporation of America Holdings (NYSE: LH), Health Net, Inc.
(NYSE: HNT), and CombiMatrix Corporation (NASDAQ: CBMX). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Quest Diagnostics Incorporated Research Report

In the recently held HIMSS 2013 Conference, Quest Diagnostics presented its
award-winning healthcare information technology (HIT) connectivity solutions.
The company is known for offering the broadest access to diagnostic
information services through its network of laboratories and through its HIT
network. Quest Diagnostics' HIT connectivity solutions support multiple
healthcare stakeholders, integrate platforms, and optimize workflows
strategically across health systems. Continuing to provide groundbreaking
solutions, the company has been recognized in FORTUNE magazine's World's Most
Admired Companies list as the No. 1 company under the "Pharmacy and Other
Services" category. The Full Research Report on Quest Diagnostics Incorporated
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/6bc0_DGX]

--

Life Technologies Corporation Research Report

Under a collaborative agreement and related license with Harvard University,
Life Technologies acquired exclusive rights to develop a panel of
characterization tests designed to evaluate hPS cells for their use in a
variety of discovery and translational research applications. The license
expands Life Technologies' portfolio of stem cell research products and
deepens its commitment to customers in the field. Considered a growing segment
in the field, the global stem cell characterization market is currently
estimated to be $30 million annually. The overall market for stem cell
research tools is approximately $1 billion. The Full Research Report on Life
Technologies Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/cd9d_LIFE]

--

Laboratory Corporation of America Holdings Research Report

Complimenting diseased focused approach to diagnostic testing, LabCorp
launched its clinical next generation sequencing test, GeneSeq: Cardio for
genetic causes of familial cardiac disease. GeneSeq: Cardio complements the
company's broad testing menu and enhanced reporting for cardiovascular
disease. This sequencing test is considered to be a significant milestone for
the company as LabCorp embraces new technologies and bioinformatics to further
its ability to service patients and physicians. For 2013 LabCorp expects
revenue growth of around two to three percent, and operating cash flow of $870
million to $900 million. The Full Research Report on Laboratory Corporation of
America Holdings - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/96dc_LH]

--

Health Net, Inc. Research Report

Health Net Foundation, the charitable foundation of Health Net, is awarding
$150,000 in total grants to Northeast Valley Health Corporation for the launch
of Project CARES, a new in-home care program in Los Angeles County. The grant
is expected to enhance delivery of healthcare services, enabling healthcare
providers to expand their reach and their services to focus more in the
medically underserved residents of the community. On March 13, Health Net is
set to present at the Barclays Healthcare Conference. The Full Research Report
on Health Net, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/b9f6_HNT]

--

CombiMatrix Corporation Research Report

As of March 11, CombiMatrix went up 30.72 percent on 2.1 million shares
traded. The molecular diagnostics company's 2012 revenue increased to $5.4
million, up 15 percent from the previous year. Revenue from the company's core
prenatal testing markets grew by more than 101 percent over the comparable
prior year, driven by a 171 percent increase in billable test volumes
year-over-year. The momentum is expected to continue in 2013, as CombiMatrix
continues to refine its selling organization and approach to take advantage of
the prenatal market opportunity. The de-emphasized oncology business segment
is also expected to stabilize, allowing for strong year-over-year top line
growth. The Full Research Report on CombiMatrix Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/4e57_CBMX]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
press@investors-alliance.com
+1-480-745-7826

SOURCE Investors-Alliance
 
Press spacebar to pause and continue. Press esc to stop.